The Future of IPOs Seems Bright for Life Sciences

In the current IPOs market environment, recently started biotech companies have found it challenging to get funding for research within Europe. However, in the United States, venture companies have seen considerable investments in this field.

There were at least 60 life sciences IPOs in 2019 alone. That is double the number as compared to that of technology IPOs the same year. More than 50 percent of these companies were in the biotech sector. 16 were concerned with medical devices and 10 with the pharmaceutical industry. However, the large number of these IPOs is not the only factor in question.

The sizes of the deal value for life sciences companies were much smaller than the ones connected to tech issuers. Of all the life sciences IPOs, around four of them had deal values exceedi...

Login In

or

Register now for free access

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments